Compare BLZE & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLZE | DRTS |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.4M | 300.2M |
| IPO Year | 2021 | N/A |
| Metric | BLZE | DRTS |
|---|---|---|
| Price | $4.94 | $3.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $9.50 | $9.00 |
| AVG Volume (30 Days) | ★ 884.2K | 62.0K |
| Earning Date | 11-06-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $141,859,000.00 | N/A |
| Revenue This Year | $16.43 | N/A |
| Revenue Next Year | $11.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.73 | N/A |
| 52 Week Low | $3.94 | $2.30 |
| 52 Week High | $10.86 | $4.69 |
| Indicator | BLZE | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 33.89 | 51.07 |
| Support Level | $4.50 | $3.67 |
| Resistance Level | $4.78 | $4.28 |
| Average True Range (ATR) | 0.26 | 0.25 |
| MACD | 0.18 | 0.03 |
| Stochastic Oscillator | 97.65 | 55.29 |
Backblaze Inc provides cloud storage services. The company offers services such as Backblaze B2 Cloud Storage, which enables customers to store data, developers to build applications, and partners to expand their use cases. It is offered as a consumption-based Infrastructure-as-a-Service (IaaS) and serves use cases including backups, multi-cloud, application development, and ransomware protection and Backblaze Computer Backup automatically backs up data from laptops and desktops for businesses and individuals. Geographically, it derives a majority of revenue from the United States and the rest from the United Kingdom, Canada, and Other regions.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.